DK3003284T3 - Farmaceutiske formuleringer af en hif-hydroxylase-inhibitor - Google Patents

Farmaceutiske formuleringer af en hif-hydroxylase-inhibitor Download PDF

Info

Publication number
DK3003284T3
DK3003284T3 DK14735770.1T DK14735770T DK3003284T3 DK 3003284 T3 DK3003284 T3 DK 3003284T3 DK 14735770 T DK14735770 T DK 14735770T DK 3003284 T3 DK3003284 T3 DK 3003284T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical formulations
hydroxylase inhibitor
hif hydroxylase
hif
inhibitor
Prior art date
Application number
DK14735770.1T
Other languages
English (en)
Inventor
David Conca
Lee Allen Flippin
Scott David Leigh
Claudia Witschi
Lee Robert Wright
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51063834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3003284(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Application granted granted Critical
Publication of DK3003284T3 publication Critical patent/DK3003284T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK14735770.1T 2013-06-06 2014-06-05 Farmaceutiske formuleringer af en hif-hydroxylase-inhibitor DK3003284T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361831909P 2013-06-06 2013-06-06
PCT/US2014/041021 WO2014197660A1 (en) 2013-06-06 2014-06-05 Pharmaceutical formulations of a hif hydroxylase inhibitor

Publications (1)

Publication Number Publication Date
DK3003284T3 true DK3003284T3 (da) 2020-03-30

Family

ID=51063834

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14735770.1T DK3003284T3 (da) 2013-06-06 2014-06-05 Farmaceutiske formuleringer af en hif-hydroxylase-inhibitor

Country Status (24)

Country Link
US (3) US20160120859A1 (da)
EP (2) EP3708154A1 (da)
JP (4) JP6604941B2 (da)
KR (3) KR102291860B1 (da)
CN (5) CN111728951A (da)
AU (1) AU2014274890B2 (da)
CA (1) CA2914049C (da)
CY (1) CY1122951T1 (da)
DK (1) DK3003284T3 (da)
ES (1) ES2786924T3 (da)
HR (1) HRP20200615T1 (da)
HU (1) HUE049623T2 (da)
IL (3) IL296484B2 (da)
LT (1) LT3003284T (da)
ME (1) ME03777B (da)
MX (3) MX2015016536A (da)
PL (1) PL3003284T3 (da)
PT (1) PT3003284T (da)
RS (1) RS60464B1 (da)
SG (1) SG11201509764RA (da)
SI (1) SI3003284T1 (da)
SM (1) SMT202000190T1 (da)
WO (1) WO2014197660A1 (da)
ZA (1) ZA201508712B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103145616B (zh) 2003-06-06 2015-09-30 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
NZ592741A (en) 2008-11-14 2013-03-28 Fibrogen Inc Thiochromene derivatives as hif hydroxylase inhibitors
PL2872488T3 (pl) 2012-07-16 2019-01-31 Fibrogen, Inc. Postacie krystaliczne inhibitora hydroksylazy prolilowej
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
CN103435546B (zh) 2012-07-16 2016-08-10 菲布罗根有限公司 制备异喹啉化合物的方法
IL296484B2 (en) 2013-06-06 2025-03-01 Fibrogen Inc Pharmaceutical formulations of HIF hydroxylase inhibitor
SI3277270T1 (sl) * 2015-04-01 2022-04-29 Akebia Therapeutics, Inc. Sestavki in postopki za zdravljenje anemije
WO2019042485A1 (en) 2017-08-30 2019-03-07 Zentiva, K.S. FORMS IN THE STRONG STATE OF ROXADUSTAT
ES2898878T3 (es) 2017-09-04 2022-03-09 Sandoz Ag Cocristal de un inhibidor de la prolil·hidroxilasa de HIF disponible por vía oral
CN110664814A (zh) * 2019-10-24 2020-01-10 上海长海医院 Fg-4592在制备治疗炎性肠病药物中的用途
CN110934833B (zh) * 2019-12-17 2022-08-19 河北长天药业有限公司 一种复方氨酚那敏颗粒
EP4121009A4 (en) * 2020-03-17 2024-04-17 Zydus Lifesciences Limited Formulation comprising hif prolyl hydroxylase inhibitors
US20220280482A1 (en) * 2021-03-06 2022-09-08 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
CN116832005A (zh) * 2022-03-23 2023-10-03 石药集团中奇制药技术（石家庄）有限公司 一种罗沙司他胶囊
CN114796280B (zh) * 2022-06-15 2024-06-25 河北长天药业有限公司 一种复方氨酚那敏颗粒及其制备工艺
EP4321155A1 (en) 2022-08-08 2024-02-14 Sanovel Ilac Sanayi Ve Ticaret A.S. An oral pharmaceutical composition comprising roxadustat
WO2025111214A1 (en) 2023-11-22 2025-05-30 Fibrogen, Inc. [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3- carbonyl)amino]acetic acid (roxadustat) for the treatment of anemia in subjects with myelodysplastic syndrome (mds)
CN118436652A (zh) * 2024-04-18 2024-08-06 南方医科大学顺德医院(佛山市顺德区第一人民医院) 一种罗沙司他药物制剂及其应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59401924D1 (de) 1993-11-02 1997-04-10 Hoechst Ag Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
US8318703B2 (en) 2001-12-06 2012-11-27 Fibrogen, Inc. Methods for improving kidney function
CN100522946C (zh) 2001-12-06 2009-08-05 法布罗根股份有限公司 低氧诱导因子(HIF)α的稳定化
DE10209692A1 (de) 2002-03-06 2003-09-18 Merck Patent Gmbh Isochinolinderivate
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
JP4805234B2 (ja) * 2002-12-16 2011-11-02 キッセイ薬品工業株式会社 経口固形医薬
BR0317349A (pt) 2002-12-16 2005-11-16 Kissei Pharmaceutical Droga sólida para uso oral
CN103145616B (zh) 2003-06-06 2015-09-30 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
EP1658074B1 (en) 2003-08-01 2012-11-07 Fibrogen, Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
US7718797B2 (en) 2004-03-16 2010-05-18 Asahi Kasei Pharma Corporation Fasudil-containing preparation and method of improving stability thereof
CN101166745A (zh) 2005-03-02 2008-04-23 菲布罗根有限公司 噻吩并吡啶化合物和其使用方法
JP5390184B2 (ja) 2005-06-06 2014-01-15 ファイブローゲン、インコーポレーテッド 貧血の改良された治療方法
CN101242817B (zh) 2005-06-15 2016-08-31 菲布罗根公司 HIF1α调节剂在治疗癌症中的用途
UA97349C2 (uk) 2005-09-08 2012-02-10 Х. Луннбэк А/С Стійкі тверді склади сертиндолу
ATE537827T1 (de) 2005-10-31 2012-01-15 Kowa Co Pharmazeutische zubereitung mit hervorragender photostabilität
GB0523810D0 (en) 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
EP2044028B1 (en) 2006-01-27 2012-05-16 Fibrogen, Inc. Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif)
JP2009526047A (ja) * 2006-02-09 2009-07-16 テバ ファーマシューティカル インダストリーズ リミティド モンテルカストナトリウムの安定な医薬製剤
KR20080097446A (ko) 2006-02-16 2008-11-05 피브로겐, 인크. 뇌졸중의 치료를 위한 화합물과 방법
BRPI0710527B8 (pt) 2006-04-04 2021-05-25 Fibrogen Inc compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
WO2007141743A2 (en) * 2006-06-06 2007-12-13 Ranbaxy Laboratories Limited A tablet dosage form comprising cetirizine and pseudoephedrine
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
JP5683058B2 (ja) 2007-04-27 2015-03-11 ニプロ株式会社 経口固形製剤及びその製造方法
EP2433620A1 (en) * 2007-10-12 2012-03-28 AstraZeneca AB Zibotentan Composition
AU2008319229A1 (en) 2007-11-02 2009-05-07 Fibrogen, Inc. Methods for reducing blood pressure
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
US20110039885A1 (en) 2007-12-06 2011-02-17 Fibrogen, Inc. Methods for increasing endothelial progenitor cells
WO2009075826A1 (en) 2007-12-07 2009-06-18 Fibrogen, Inc. Methods for increasing white blood cells
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
US8217043B2 (en) 2008-08-20 2012-07-10 Fibrogen, Inc. Compounds and methods for their use
EP2341904A1 (en) 2008-08-26 2011-07-13 Fibrogen, Inc. Methods for treatment of multiple sclerosis
NZ592741A (en) 2008-11-14 2013-03-28 Fibrogen Inc Thiochromene derivatives as hif hydroxylase inhibitors
US20100144737A1 (en) 2008-12-08 2010-06-10 Fibrogen, Inc. Methods for inhibiting t helper cell differentiation
CN102300563A (zh) 2009-01-29 2011-12-28 大日本住友制药株式会社 具有内核的口腔崩解片剂
JP2010248106A (ja) * 2009-04-14 2010-11-04 Dainippon Sumitomo Pharma Co Ltd フィルムコーティング錠
JP2012176899A (ja) * 2009-05-19 2012-09-13 Mitsubishi Tanabe Pharma Corp ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
US20140057941A1 (en) 2011-01-13 2014-02-27 Kin-Hung (Peony) Yu Methods For Increasing Mean Corpuscular Volume
CN103429239A (zh) * 2011-01-13 2013-12-04 菲布罗根有限公司 增加网织红细胞血红蛋白含量的方法
CN103608346B (zh) 2011-02-02 2016-06-15 菲布罗根有限公司 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物
ES2606631T3 (es) 2011-07-22 2017-03-24 Beijing Betta Pharmaceuticals Co., Ltd Formas polimeróficas de compuestos como inhibidor de la prolila hidroxilasa, y usos de los mismos
US20140309256A1 (en) * 2011-11-09 2014-10-16 Fibrogen, Inc. Therapeutic Method
CA2866556C (en) 2012-03-09 2020-01-07 Fibrogen, Inc. 4 -hydroxy-isoquinoline compounds as hif hydroxylase inhibitors
CN103435546B (zh) 2012-07-16 2016-08-10 菲布罗根有限公司 制备异喹啉化合物的方法
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
PL2872488T3 (pl) 2012-07-16 2019-01-31 Fibrogen, Inc. Postacie krystaliczne inhibitora hydroksylazy prolilowej
JP6437456B2 (ja) 2013-01-24 2018-12-12 フィブロジェン インコーポレイテッド ｛［１−シアノ−５−（４−クロロフェノキシ）−４−ヒドロキシ−イソキノリン−３−カルボニル］−アミノ｝−酢酸の結晶形態
IL296484B2 (en) 2013-06-06 2025-03-01 Fibrogen Inc Pharmaceutical formulations of HIF hydroxylase inhibitor

Also Published As

Publication number Publication date
IL242759B2 (en) 2023-05-01
ZA201508712B (en) 2020-07-29
ME03777B (me) 2021-04-20
RU2681304C2 (ru) 2019-03-06
JP2016523846A (ja) 2016-08-12
KR102291860B1 (ko) 2021-08-20
US20160120859A1 (en) 2016-05-05
US20190008846A1 (en) 2019-01-10
SI3003284T1 (sl) 2020-08-31
HRP20200615T1 (hr) 2020-07-10
EP3003284B1 (en) 2020-02-12
IL298998A (en) 2023-02-01
NZ714554A (en) 2021-06-25
IL242759A (da) 2015-12-31
CY1122951T1 (el) 2021-10-29
IL296484B1 (en) 2024-11-01
IL296484B2 (en) 2025-03-01
EP3708154A1 (en) 2020-09-16
CN111728951A (zh) 2020-10-02
LT3003284T (lt) 2020-04-27
HK1222550A1 (en) 2017-07-07
AU2014274890A1 (en) 2015-12-17
IL298998B1 (en) 2024-03-01
CN105377242A (zh) 2016-03-02
RS60464B1 (sr) 2020-07-31
EP3003284A1 (en) 2016-04-13
PT3003284T (pt) 2020-08-10
HUE049623T2 (hu) 2020-09-28
CA2914049A1 (en) 2014-12-11
BR112015029693A8 (pt) 2019-12-24
US10765672B2 (en) 2020-09-08
AU2014274890B2 (en) 2019-10-03
JP2021100971A (ja) 2021-07-08
BR112015029693A2 (pt) 2017-07-25
JP6604941B2 (ja) 2019-11-13
RU2015151056A (ru) 2017-07-14
RU2015151056A3 (da) 2018-05-03
SG11201509764RA (en) 2015-12-30
JP6861758B2 (ja) 2021-04-21
CA2914049C (en) 2021-10-12
IL296484A (en) 2022-11-01
SMT202000190T1 (it) 2020-05-08
IL298998B2 (en) 2024-07-01
MX2022011225A (es) 2022-10-07
NZ754196A (en) 2021-06-25
PL3003284T3 (pl) 2020-08-10
MX2015016536A (es) 2016-08-11
IL242759B1 (en) 2023-01-01
KR20220164069A (ko) 2022-12-12
JP2023068197A (ja) 2023-05-16
KR20210104173A (ko) 2021-08-24
JP2019137703A (ja) 2019-08-22
CN110448537A (zh) 2019-11-15
MX2020003096A (es) 2020-08-17
CN111728952A (zh) 2020-10-02
US20220054474A1 (en) 2022-02-24
KR20160018514A (ko) 2016-02-17
ES2786924T3 (es) 2020-10-14
WO2014197660A1 (en) 2014-12-11
CN111728950A (zh) 2020-10-02

Similar Documents

Publication Publication Date Title
DK3003284T3 (da) Farmaceutiske formuleringer af en hif-hydroxylase-inhibitor
IL269227B (en) Solid forms of treprostinil
DK3080100T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3068776T3 (da) Inhibitorer af replikation af influenzavira
DK2968529T3 (da) Fremstilling af jordnøddeformuleringer til oral desensibilisering
HUE054212T2 (hu) Szelektív CDK4/6 inhibitor szilárd formái
DK3027618T3 (da) Polymorf af syk-hæmmere
DK2961388T3 (da) Kombinationer af lægemidler
LT3030227T (lt) Prailginto atpalaidavimo jak1 inhibitoriaus dozavimo formos
DK2968221T3 (da) Farmaceutisk sammensætning af s-ketaminhydrochlorid
DK3066085T3 (da) Fremgangsmåde til syntesen af en indolamin-2,3-dioxygenaseinhibitor
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
PL2872488T3 (pl) Postacie krystaliczne inhibitora hydroksylazy prolilowej
DK3157508T3 (da) Fast oral doseringsform af lipofile forbindelser
DK2961766T3 (da) Kvantificering af vaccinesammensætninger
DK2968214T3 (da) Hidtil ukendte analgetiske sammensætninger
DK2970389T3 (da) Farmaceutiske forbindelser
SI3293176T1 (sl) Kristalna oblika inhibitorja PDE4
DK3106150T3 (da) Forbedrede farmaceutiske sammensætninger af pimobendan
EP2961397A4 (en) TRANSDERMAL FORMULATIONS
DK3562487T3 (da) Metalloenzyminhibitorforbindelser
EP3632467C0 (en) COMPLEMENT FACTOR H INHIBITORS
EP2968275A4 (en) LXR MODULATORS
DK3418273T3 (da) Derivater af flavagliner
DK3066089T3 (da) Substituerede n-acetyl-l-cysteinderivater og relaterede forbindelser